MicroPort CardioFlow Medtech Corporation announced a discloseable and connected transaction to acquire the remaining 49% equity interest in MP CardioAdvent. This acquisition, detailed in an agreement dated May 30, 2025, involves purchasing approximately 35.27% from MicroPort Sinica and 13.73% from Shanghai Zuoqing. Upon completion, MP CardioFlow will fully own MP CardioAdvent, enhancing its focus on innovative solutions for structural heart diseases. The transaction, subject to regulatory approvals, is significant under the listing rules due to its size.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。